Background Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage.
Corticosteroids may modulate immune-mediated lung injury and reducing progression to …

Importance Effective therapies for patients with coronavirus disease 2019 (COVID-19) are
needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced …

Background Lowering LDL cholesterol with statin regimens reduces the risk of myocardial
infarction, ischaemic stroke, and the need for coronary revascularisation in people without …

Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis
of in vitro activity, preclinical studies, and observational studies. Here, we report the results …

Background Several countries affected by the COVID-19 pandemic have reported a substantial
drop in the number of patients attending the emergency department with acute coronary …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors
reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart …

Background Statin therapy has been shown to reduce major vascular events and vascular
mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety …

This publication describes uniform definitions for cardiovascular and stroke outcomes
developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the US …

Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 …

Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin (IL)-6,
reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …